New drug trial targets tough stomach cancers after standard treatments fail
NCT ID NCT07115485
Summary
This study is testing an experimental drug called HLX43 for people with advanced stomach or gastroesophageal junction cancer that has continued to grow despite standard treatments. The trial aims to find a safe and effective dose while measuring how well the drug shrinks tumors and controls the disease. About 60 participants will receive HLX43 through an IV at different dose levels to determine which works best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.